

Marjorie G Zauderer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5319752/publications.pdf>

Version: 2024-02-01

49
papers

3,501
citations

201674

27
h-index

206112

48
g-index

51
all docs

51
docs citations

51
times ranked

4449
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-------|-----------|
| 1 | Developing a cancer-specific geriatric assessment. <i>Cancer</i> , 2005, 104, 1998-2005. | 4.1 | 541 |
| 2 | Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565. | 9.4 | 422 |
| 3 | Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429. | 329.8 | 306 |
| 4 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11. | 28.9 | 223 |
| 5 | A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763. | 9.4 | 222 |
| 6 | Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768. | 1.6 | 154 |
| 7 | Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1278-1283. | 0.8 | 142 |
| 8 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770. | 3.7 | 119 |
| 9 | Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884. | 7.0 | 103 |
| 10 | Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 84, 271-274. | 2.0 | 101 |
| 11 | Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667. | 1.1 | 85 |
| 12 | Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1430-1433. | 1.1 | 81 |
| 13 | New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment. <i>Clinical Cancer Research</i> , 2012, 18, 4485-4490. | 7.0 | 77 |
| 14 | V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 303-311. | 5.5 | 65 |
| 15 | Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401. | 0.8 | 55 |
| 16 | Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 249-255. | 1.1 | 53 |
| 17 | Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 993-1000. | 1.1 | 53 |
| 18 | EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767. | 10.7 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 205-210. | 2.5 | 48 |
| 20 | A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489. | 7.0 | 48 |
| 21 | Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 151-156. | 2.5 | 47 |
| 22 | Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. <i>Lung Cancer</i> , 2014, 86, 237-240. | 2.0 | 47 |
| 23 | The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2011, 12, 163-172. | 3.0 | 37 |
| 24 | Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. <i>Genome Medicine</i> , 2019, 11, 18. | 8.2 | 36 |
| 25 | Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study. <i>International Journal of Cancer</i> , 2017, 140, 1976-1984. | 5.1 | 35 |
| 26 | A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1272-1277. | 1.1 | 33 |
| 27 | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses $\text{NF-}\kappa\text{B}$ Loss-Driven Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1693-1704. | 4.1 | 31 |
| 28 | Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. <i>Oncotarget</i> , 2017, 8, 77872-77882. | 1.8 | 31 |
| 29 | Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. <i>Lancet Oncology</i> , 2016, 17, e43-e44. | 10.7 | 28 |
| 30 | Molecular Characterization of Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2022, 17, 455-460. | 1.1 | 24 |
| 31 | The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576. | 12.3 | 23 |
| 32 | Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 42-47. | 4.9 | 22 |
| 33 | Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69. | 0.8 | 19 |
| 34 | Toxicity of initial chemotherapy in older patients with lung cancers. <i>Journal of Geriatric Oncology</i> , 2013, 4, 64-70. | 1.0 | 18 |
| 35 | Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063. | 2.5 | 17 |
| 36 | Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9. | 2.0 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | A new standard for malignant pleural mesothelioma. <i>Lancet, The</i> , 2016, 387, 1352-1354. | 13.7 | 14 |
| 38 | Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. <i>Drugs and Aging</i> , 2005, 22, 709-715. | 2.7 | 13 |
| 39 | Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry. <i>American Journal of Industrial Medicine</i> , 2020, 63, 105-114. | 2.1 | 12 |
| 40 | Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015, 2015, 170-172. | 0.4 | 11 |
| 41 | Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459. | 2.5 | 10 |
| 42 | Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 487-90. | 1.7 | 9 |
| 43 | Nivo-lution in Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5438-5440. | 7.0 | 7 |
| 44 | Leptomeningeal Metastases from Small Cell Lung Cancer Responsive to Temozolomide Therapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1716-1717. | 1.1 | 5 |
| 45 | The therapeutic implications of the genomic analysis of malignant pleural mesothelioma. <i>Nature Communications</i> , 2021, 12, 1819. | 12.8 | 3 |
| 46 | Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy. <i>Journal of Immunotherapy</i> , 2021, Publish Ahead of Print, . | 2.4 | 3 |
| 47 | Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. <i>Oncologist</i> , 2022, 27, 610-614. | 3.7 | 2 |
| 48 | Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. <i>Current Cancer Research</i> , 2017, , 313-345. | 0.2 | 1 |
| 49 | Novel and Targeted Therapies. , 2012, , 95-101. | | 0 |